About GreyScan

Using Capillary Zone Electrophoresis (CZE) to create world changing technology within the security, defence, pharmaceutical and medical industries.

Who We Are

GreyScan Australia Pty Ltd is the inventor and manufacturer of Australian trace detection technology. Established in 2015 to develop and commercialise the ETD-100 inorganic explosive trace detector, GreyScan established its home in Port Melbourne in 2018, where it continues to develop and manufacture ground-breaking screening tools for global demand. Since the initial award-winning R&D undertaken in conjunction with the University of Tasmania (GreyScan was awarded the 2019 Eureka Prize for Outstanding Science in Safeguarding Australia), GreyScan has invested $35M to grow its manufacturing facilities in Australia. GreyScan’s ETD-100 has been developed over a number of years and with significant private and government investment to be fast, accurate, portable and easy to use. The ETD-100 is in use by global Government agencies including the Australian Federal Police and German Federal Police, as a valuable tool in the detection of explosives.

The ETD-100 is now in full series production in Port Melbourne and is generating sales revenue locally and through exports to global Government customers, the result of which, was a 2020 Export Achievement Award from the Victorian Government. GreyScan is now seeking to expedite the manufacture and commercialisation of its innovative screening platform to produce the TVD-1 & TVD-2; two products, which are capable of detecting viruses including SARS-COV-2. These ground-breaking products will enable the local and global economies to open quickly and safely by identifying sources of outbreaks, whilst providing fast, accurate and portable screening, that removes intrusive and time-consuming sampling, and result phase offered by current capability. Whilst the nation and the world are rolling out vaccines, the ability to assess the likelihood of getting sick or being infectious is not yet being measured. Whether an individual remains vaccinated or not, continues to be a critical capability gap.

Current testing solutions which involve taking an intrusive swab from the throat or nose are not able to determine whether the SARS-COV-2 is active, infective, or a risk to others. These tests also require long lead times.

Workplaces, schools, transport hubs, events, sports and leisure activities, border crossing stations, and aged care facilities, amongst many others, will use the TVD system for fast accurate mass screening for infectivity. As the TVD has digital networking capabilities, the aggregated data can be utilised to provide regional, national, and global trends, and early warning systems on virus patterns on SARS-COV-2, its variants and any future virus threats.



Board of Directors

Executive Team

Global Advisory Board